Kardigan, Inc. (NASDAQ:KARD)
| Market Cap | $1.16B-40.9% |
| Revenue (ttm) | $0 |
| Net Income | -$230.88M |
| EPS | -$2.78 |
| Shares Out | 89.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 64,009 |
| Open | $13.91 |
| Previous Close | $14.12 |
| Day's Range | $13.00 - $14.36 |
| 52-Week Range | $12.23 - $27.00 |
| Beta | 6.05 |
| Analysts | Buy |
| Price Target | $39.00(+200.00%) |
| Earnings Date | Feb 11, 2027 |
About KARD
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
When insiders bought and sold
1 year · open-market trades onlyAnalyst consensus
1 firm rating KARD in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 11, 2027Earnings report
$KARD stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in KARD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KARD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KARD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New KARD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KARD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in KARD
| VTIVanguard Morningstar Total Stock Market ETF | $13.39M |
| IWMiShares Russell 2000 ETF | $11.44M |
| VXFVanguard Extended Market ETF | $4.39M |
| IWOiShares Russell 2000 Growth ETF | $2.50M |
| VTWOVanguard Russell 2000 ETF | $2.43M |
| SCHASchwab U.S. Small-Cap ETF | $1.94M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from KARD’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
Upcoming unlocks
ETFs that hold this stock
| ESLG | Eventide Large Cap Growth ETF | 0.47% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.47% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 0.36% |
| TSEE | T. Rowe Price Small Cap ETF | 0.28% |
| PJSM | PGIM Jennison Small-Mid Cap Core Equity ETF | 0.14% |
Weight is the stock’s share of each fund’s holdings.